カテゴリー： QYResearch, 世界, 医療/バイオ

新型コロナウイルス感染症用デキサメタゾンの世界市場インサイト・予測（～2028年）

【英語タイトル】Global Dexamethasone for COVID-19 Market Insights and Forecast to 2028

QYResearchが出版した調査資料（QY22MA00001）・商品コード：QY22MA00001
・発行会社（調査会社）：QYResearch
・発行日：2022年3月
・ページ数：127
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD4,900 ⇒換算￥637,000見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD7,350 ⇒換算￥955,500見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD9,800 ⇒換算￥1,274,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
新型コロナウイルス感染症のパンデミックにより、世界の新型コロナウイルス感染症用デキサメタゾンの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に新型コロナウイルス感染症用デキサメタゾンの世界市場のxxx％を占める「97%純度」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
中国の新型コロナウイルス感染症用デキサメタゾンの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの新型コロナウイルス感染症用デキサメタゾン市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの新型コロナウイルス感染症用デキサメタゾン市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

新型コロナウイルス感染症用デキサメタゾンのグローバル主要メーカーには、Pfizer、Novartis、Merck & Co.、Sanofi Pharmaceuticals、Baxter International、Zydus Cadila、Endo International、Aspen Pharmacare Holdings、Hikma Pharmaceuticals、Cipla Limited、Wockhardt Limited、Xspire Pharmaceuticals、Fera Pharmaceuticals、Aché Laboratórios、WraSer Pharmaceuticals、Mylan、Bound Tree Medical、Santa Cruz Biotechnology、KingYork、Lingrui Pharmaceutical、North China Pharmaceutical、Shanghai Shyndec Pharmaceutical、Pharscin Pharmaceutical、China Resources Sanjiu Pharmaceutical、Reyphon Pharmaceuticalなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

新型コロナウイルス感染症用デキサメタゾン市場は、種類と用途によって区分されます。世界の新型コロナウイルス感染症用デキサメタゾン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
97%純度、99%純度、その他

【用途別セグメント】
病院、診療所、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 新型コロナウイルス感染症用デキサメタゾン製品概要
- 種類別市場（97%純度、99%純度、その他）
- 用途別市場（病院、診療所、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界の新型コロナウイルス感染症用デキサメタゾン販売量予測2017-2028
- 世界の新型コロナウイルス感染症用デキサメタゾン売上予測2017-2028
- 新型コロナウイルス感染症用デキサメタゾンの地域別販売量
- 新型コロナウイルス感染症用デキサメタゾンの地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別新型コロナウイルス感染症用デキサメタゾン販売量
- 主要メーカー別新型コロナウイルス感染症用デキサメタゾン売上
- 主要メーカー別新型コロナウイルス感染症用デキサメタゾン価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（97%純度、99%純度、その他）
- 新型コロナウイルス感染症用デキサメタゾンの種類別販売量
- 新型コロナウイルス感染症用デキサメタゾンの種類別売上
- 新型コロナウイルス感染症用デキサメタゾンの種類別価格
・用途別市場規模（病院、診療所、その他）
- 新型コロナウイルス感染症用デキサメタゾンの用途別販売量
- 新型コロナウイルス感染症用デキサメタゾンの用途別売上
- 新型コロナウイルス感染症用デキサメタゾンの用途別価格
・北米市場
- 北米の新型コロナウイルス感染症用デキサメタゾン市場規模（種類別、用途別）
- 主要国別の新型コロナウイルス感染症用デキサメタゾン市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの新型コロナウイルス感染症用デキサメタゾン市場規模（種類別、用途別）
- 主要国別の新型コロナウイルス感染症用デキサメタゾン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の新型コロナウイルス感染症用デキサメタゾン市場規模（種類別、用途別）
- 主要国別の新型コロナウイルス感染症用デキサメタゾン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の新型コロナウイルス感染症用デキサメタゾン市場規模（種類別、用途別）
- 主要国別の新型コロナウイルス感染症用デキサメタゾン市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの新型コロナウイルス感染症用デキサメタゾン市場規模（種類別、用途別）
- 主要国別の新型コロナウイルス感染症用デキサメタゾン市場規模（トルコ、サウジアラビア）
・企業情報
Pfizer、Novartis、Merck & Co.、Sanofi Pharmaceuticals、Baxter International、Zydus Cadila、Endo International、Aspen Pharmacare Holdings、Hikma Pharmaceuticals、Cipla Limited、Wockhardt Limited、Xspire Pharmaceuticals、Fera Pharmaceuticals、Aché Laboratórios、WraSer Pharmaceuticals、Mylan、Bound Tree Medical、Santa Cruz Biotechnology、KingYork、Lingrui Pharmaceutical、North China Pharmaceutical、Shanghai Shyndec Pharmaceutical、Pharscin Pharmaceutical、China Resources Sanjiu Pharmaceutical、Reyphon Pharmaceutical
・産業チェーン及び販売チャネル分析
- 新型コロナウイルス感染症用デキサメタゾンの産業チェーン分析
- 新型コロナウイルス感染症用デキサメタゾンの原材料
- 新型コロナウイルス感染症用デキサメタゾンの生産プロセス
- 新型コロナウイルス感染症用デキサメタゾンの販売及びマーケティング
- 新型コロナウイルス感染症用デキサメタゾンの主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 新型コロナウイルス感染症用デキサメタゾンの産業動向
- 新型コロナウイルス感染症用デキサメタゾンのマーケットドライバー
- 新型コロナウイルス感染症用デキサメタゾンの課題
- 新型コロナウイルス感染症用デキサメタゾンの阻害要因
・主な調査結果
【レポートの概要】

Dexamethasone for COVID-19 is a corticosteroid hormone drug. Hormones are so-called long-distance chemical messengers. These types of hormones are released from glands found on the kidneys that are known as adrenal glands. The adrenal glands mediate stress response with the production of these corticosteroid messengers. Dexamethasone is a synthetic source of corticosteroid hormones. When taken, Dexamethasone will enter the bloodstream and perform similar regulatory tasks as natural corticosteroids, namely decrease the immune response, and reduce inflammation/swelling/allergic-type reactions. the severe inflammation of vital organs caused by the body’s response to COVID-19 seems to be the leading cause of coronavirus deaths. Dexamethasone can reduce risk of dying in critically ill patients.
Market Analysis and Insights: Global Dexamethasone for COVID-19 Market
Due to the COVID-19 pandemic, the global Dexamethasone for COVID-19 market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 97% Purity accounting for % of the Dexamethasone for COVID-19 global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Dexamethasone for COVID-19 market size is valued at US$ million in 2021, while the US and Europe Dexamethasone for COVID-19 are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Dexamethasone for COVID-19 landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Dexamethasone for COVID-19 include Pfizer, Novartis, Merck & Co., Sanofi Pharmaceuticals, Baxter International, Zydus Cadila, Endo International, Aspen Pharmacare Holdings and Hikma Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Dexamethasone for COVID-19 Scope and Segment
Dexamethasone for COVID-19 market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Dexamethasone for COVID-19 market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
97% Purity
99% Purity
Others
Segment by Application
Hospitals
Clinics
Others
By Company
Pfizer
Novartis
Merck & Co.
Sanofi Pharmaceuticals
Baxter International
Zydus Cadila
Endo International
Aspen Pharmacare Holdings
Hikma Pharmaceuticals
Cipla Limited
Wockhardt Limited
Xspire Pharmaceuticals
Fera Pharmaceuticals
Aché Laboratórios
WraSer Pharmaceuticals
Mylan
Bound Tree Medical
Santa Cruz Biotechnology
KingYork
Lingrui Pharmaceutical
North China Pharmaceutical
Shanghai Shyndec Pharmaceutical
Pharscin Pharmaceutical
China Resources Sanjiu Pharmaceutical
Reyphon Pharmaceutical
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

【レポートの目次】

1 Study Coverage
1.1 Dexamethasone for COVID-19 Product Introduction
1.2 Market by Type
1.2.1 Global Dexamethasone for COVID-19 Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 97% Purity
1.2.3 99% Purity
1.2.4 Others
1.3 Market by Application
1.3.1 Global Dexamethasone for COVID-19 Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Dexamethasone for COVID-19 Sales Estimates and Forecasts 2017-2028
2.2 Global Dexamethasone for COVID-19 Revenue Estimates and Forecasts 2017-2028
2.3 Global Dexamethasone for COVID-19 Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Dexamethasone for COVID-19 Sales by Region
2.4.1 Global Dexamethasone for COVID-19 Sales by Region (2017-2022)
2.4.2 Global Sales Dexamethasone for COVID-19 by Region (2023-2028)
2.5 Global Dexamethasone for COVID-19 Revenue by Region
2.5.1 Global Dexamethasone for COVID-19 Revenue by Region (2017-2022)
2.5.2 Global Dexamethasone for COVID-19 Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Dexamethasone for COVID-19 Sales by Manufacturers
3.1.1 Global Top Dexamethasone for COVID-19 Manufacturers by Sales (2017-2022)
3.1.2 Global Dexamethasone for COVID-19 Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Dexamethasone for COVID-19 in 2021
3.2 Global Dexamethasone for COVID-19 Revenue by Manufacturers
3.2.1 Global Dexamethasone for COVID-19 Revenue by Manufacturers (2017-2022)
3.2.2 Global Dexamethasone for COVID-19 Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Dexamethasone for COVID-19 Revenue in 2021
3.3 Global Dexamethasone for COVID-19 Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Dexamethasone for COVID-19 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Dexamethasone for COVID-19 Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Dexamethasone for COVID-19 Sales by Type
4.1.1 Global Dexamethasone for COVID-19 Historical Sales by Type (2017-2022)
4.1.2 Global Dexamethasone for COVID-19 Forecasted Sales by Type (2023-2028)
4.1.3 Global Dexamethasone for COVID-19 Sales Market Share by Type (2017-2028)
4.2 Global Dexamethasone for COVID-19 Revenue by Type
4.2.1 Global Dexamethasone for COVID-19 Historical Revenue by Type (2017-2022)
4.2.2 Global Dexamethasone for COVID-19 Forecasted Revenue by Type (2023-2028)
4.2.3 Global Dexamethasone for COVID-19 Revenue Market Share by Type (2017-2028)
4.3 Global Dexamethasone for COVID-19 Price by Type
4.3.1 Global Dexamethasone for COVID-19 Price by Type (2017-2022)
4.3.2 Global Dexamethasone for COVID-19 Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Dexamethasone for COVID-19 Sales by Application
5.1.1 Global Dexamethasone for COVID-19 Historical Sales by Application (2017-2022)
5.1.2 Global Dexamethasone for COVID-19 Forecasted Sales by Application (2023-2028)
5.1.3 Global Dexamethasone for COVID-19 Sales Market Share by Application (2017-2028)
5.2 Global Dexamethasone for COVID-19 Revenue by Application
5.2.1 Global Dexamethasone for COVID-19 Historical Revenue by Application (2017-2022)
5.2.2 Global Dexamethasone for COVID-19 Forecasted Revenue by Application (2023-2028)
5.2.3 Global Dexamethasone for COVID-19 Revenue Market Share by Application (2017-2028)
5.3 Global Dexamethasone for COVID-19 Price by Application
5.3.1 Global Dexamethasone for COVID-19 Price by Application (2017-2022)
5.3.2 Global Dexamethasone for COVID-19 Price Forecast by Application (2023-2028)
6 North America
6.1 North America Dexamethasone for COVID-19 Market Size by Type
6.1.1 North America Dexamethasone for COVID-19 Sales by Type (2017-2028)
6.1.2 North America Dexamethasone for COVID-19 Revenue by Type (2017-2028)
6.2 North America Dexamethasone for COVID-19 Market Size by Application
6.2.1 North America Dexamethasone for COVID-19 Sales by Application (2017-2028)
6.2.2 North America Dexamethasone for COVID-19 Revenue by Application (2017-2028)
6.3 North America Dexamethasone for COVID-19 Market Size by Country
6.3.1 North America Dexamethasone for COVID-19 Sales by Country (2017-2028)
6.3.2 North America Dexamethasone for COVID-19 Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Dexamethasone for COVID-19 Market Size by Type
7.1.1 Europe Dexamethasone for COVID-19 Sales by Type (2017-2028)
7.1.2 Europe Dexamethasone for COVID-19 Revenue by Type (2017-2028)
7.2 Europe Dexamethasone for COVID-19 Market Size by Application
7.2.1 Europe Dexamethasone for COVID-19 Sales by Application (2017-2028)
7.2.2 Europe Dexamethasone for COVID-19 Revenue by Application (2017-2028)
7.3 Europe Dexamethasone for COVID-19 Market Size by Country
7.3.1 Europe Dexamethasone for COVID-19 Sales by Country (2017-2028)
7.3.2 Europe Dexamethasone for COVID-19 Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Dexamethasone for COVID-19 Market Size by Type
8.1.1 Asia Pacific Dexamethasone for COVID-19 Sales by Type (2017-2028)
8.1.2 Asia Pacific Dexamethasone for COVID-19 Revenue by Type (2017-2028)
8.2 Asia Pacific Dexamethasone for COVID-19 Market Size by Application
8.2.1 Asia Pacific Dexamethasone for COVID-19 Sales by Application (2017-2028)
8.2.2 Asia Pacific Dexamethasone for COVID-19 Revenue by Application (2017-2028)
8.3 Asia Pacific Dexamethasone for COVID-19 Market Size by Region
8.3.1 Asia Pacific Dexamethasone for COVID-19 Sales by Region (2017-2028)
8.3.2 Asia Pacific Dexamethasone for COVID-19 Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Dexamethasone for COVID-19 Market Size by Type
9.1.1 Latin America Dexamethasone for COVID-19 Sales by Type (2017-2028)
9.1.2 Latin America Dexamethasone for COVID-19 Revenue by Type (2017-2028)
9.2 Latin America Dexamethasone for COVID-19 Market Size by Application
9.2.1 Latin America Dexamethasone for COVID-19 Sales by Application (2017-2028)
9.2.2 Latin America Dexamethasone for COVID-19 Revenue by Application (2017-2028)
9.3 Latin America Dexamethasone for COVID-19 Market Size by Country
9.3.1 Latin America Dexamethasone for COVID-19 Sales by Country (2017-2028)
9.3.2 Latin America Dexamethasone for COVID-19 Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Dexamethasone for COVID-19 Market Size by Type
10.1.1 Middle East and Africa Dexamethasone for COVID-19 Sales by Type (2017-2028)
10.1.2 Middle East and Africa Dexamethasone for COVID-19 Revenue by Type (2017-2028)
10.2 Middle East and Africa Dexamethasone for COVID-19 Market Size by Application
10.2.1 Middle East and Africa Dexamethasone for COVID-19 Sales by Application (2017-2028)
10.2.2 Middle East and Africa Dexamethasone for COVID-19 Revenue by Application (2017-2028)
10.3 Middle East and Africa Dexamethasone for COVID-19 Market Size by Country
10.3.1 Middle East and Africa Dexamethasone for COVID-19 Sales by Country (2017-2028)
10.3.2 Middle East and Africa Dexamethasone for COVID-19 Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Overview
11.1.3 Pfizer Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Pfizer Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Pfizer Recent Developments
11.2 Novartis
11.2.1 Novartis Corporation Information
11.2.2 Novartis Overview
11.2.3 Novartis Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Novartis Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Novartis Recent Developments
11.3 Merck & Co.
11.3.1 Merck & Co. Corporation Information
11.3.2 Merck & Co. Overview
11.3.3 Merck & Co. Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Merck & Co. Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Merck & Co. Recent Developments
11.4 Sanofi Pharmaceuticals
11.4.1 Sanofi Pharmaceuticals Corporation Information
11.4.2 Sanofi Pharmaceuticals Overview
11.4.3 Sanofi Pharmaceuticals Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Sanofi Pharmaceuticals Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Sanofi Pharmaceuticals Recent Developments
11.5 Baxter International
11.5.1 Baxter International Corporation Information
11.5.2 Baxter International Overview
11.5.3 Baxter International Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Baxter International Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Baxter International Recent Developments
11.6 Zydus Cadila
11.6.1 Zydus Cadila Corporation Information
11.6.2 Zydus Cadila Overview
11.6.3 Zydus Cadila Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Zydus Cadila Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Zydus Cadila Recent Developments
11.7 Endo International
11.7.1 Endo International Corporation Information
11.7.2 Endo International Overview
11.7.3 Endo International Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Endo International Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Endo International Recent Developments
11.8 Aspen Pharmacare Holdings
11.8.1 Aspen Pharmacare Holdings Corporation Information
11.8.2 Aspen Pharmacare Holdings Overview
11.8.3 Aspen Pharmacare Holdings Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Aspen Pharmacare Holdings Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Aspen Pharmacare Holdings Recent Developments
11.9 Hikma Pharmaceuticals
11.9.1 Hikma Pharmaceuticals Corporation Information
11.9.2 Hikma Pharmaceuticals Overview
11.9.3 Hikma Pharmaceuticals Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Hikma Pharmaceuticals Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Hikma Pharmaceuticals Recent Developments
11.10 Cipla Limited
11.10.1 Cipla Limited Corporation Information
11.10.2 Cipla Limited Overview
11.10.3 Cipla Limited Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Cipla Limited Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Cipla Limited Recent Developments
11.11 Wockhardt Limited
11.11.1 Wockhardt Limited Corporation Information
11.11.2 Wockhardt Limited Overview
11.11.3 Wockhardt Limited Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Wockhardt Limited Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Wockhardt Limited Recent Developments
11.12 Xspire Pharmaceuticals
11.12.1 Xspire Pharmaceuticals Corporation Information
11.12.2 Xspire Pharmaceuticals Overview
11.12.3 Xspire Pharmaceuticals Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Xspire Pharmaceuticals Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Xspire Pharmaceuticals Recent Developments
11.13 Fera Pharmaceuticals
11.13.1 Fera Pharmaceuticals Corporation Information
11.13.2 Fera Pharmaceuticals Overview
11.13.3 Fera Pharmaceuticals Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Fera Pharmaceuticals Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Fera Pharmaceuticals Recent Developments
11.14 Aché Laboratórios
11.14.1 Aché Laboratórios Corporation Information
11.14.2 Aché Laboratórios Overview
11.14.3 Aché Laboratórios Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Aché Laboratórios Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Aché Laboratórios Recent Developments
11.15 WraSer Pharmaceuticals
11.15.1 WraSer Pharmaceuticals Corporation Information
11.15.2 WraSer Pharmaceuticals Overview
11.15.3 WraSer Pharmaceuticals Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 WraSer Pharmaceuticals Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 WraSer Pharmaceuticals Recent Developments
11.16 Mylan
11.16.1 Mylan Corporation Information
11.16.2 Mylan Overview
11.16.3 Mylan Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Mylan Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Mylan Recent Developments
11.17 Bound Tree Medical
11.17.1 Bound Tree Medical Corporation Information
11.17.2 Bound Tree Medical Overview
11.17.3 Bound Tree Medical Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Bound Tree Medical Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Bound Tree Medical Recent Developments
11.18 Santa Cruz Biotechnology
11.18.1 Santa Cruz Biotechnology Corporation Information
11.18.2 Santa Cruz Biotechnology Overview
11.18.3 Santa Cruz Biotechnology Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Santa Cruz Biotechnology Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Santa Cruz Biotechnology Recent Developments
11.19 KingYork
11.19.1 KingYork Corporation Information
11.19.2 KingYork Overview
11.19.3 KingYork Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 KingYork Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 KingYork Recent Developments
11.20 Lingrui Pharmaceutical
11.20.1 Lingrui Pharmaceutical Corporation Information
11.20.2 Lingrui Pharmaceutical Overview
11.20.3 Lingrui Pharmaceutical Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 Lingrui Pharmaceutical Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Lingrui Pharmaceutical Recent Developments
11.21 North China Pharmaceutical
11.21.1 North China Pharmaceutical Corporation Information
11.21.2 North China Pharmaceutical Overview
11.21.3 North China Pharmaceutical Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.21.4 North China Pharmaceutical Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.21.5 North China Pharmaceutical Recent Developments
11.22 Shanghai Shyndec Pharmaceutical
11.22.1 Shanghai Shyndec Pharmaceutical Corporation Information
11.22.2 Shanghai Shyndec Pharmaceutical Overview
11.22.3 Shanghai Shyndec Pharmaceutical Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.22.4 Shanghai Shyndec Pharmaceutical Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.22.5 Shanghai Shyndec Pharmaceutical Recent Developments
11.23 Pharscin Pharmaceutical
11.23.1 Pharscin Pharmaceutical Corporation Information
11.23.2 Pharscin Pharmaceutical Overview
11.23.3 Pharscin Pharmaceutical Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.23.4 Pharscin Pharmaceutical Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.23.5 Pharscin Pharmaceutical Recent Developments
11.24 China Resources Sanjiu Pharmaceutical
11.24.1 China Resources Sanjiu Pharmaceutical Corporation Information
11.24.2 China Resources Sanjiu Pharmaceutical Overview
11.24.3 China Resources Sanjiu Pharmaceutical Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.24.4 China Resources Sanjiu Pharmaceutical Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.24.5 China Resources Sanjiu Pharmaceutical Recent Developments
11.25 Reyphon Pharmaceutical
11.25.1 Reyphon Pharmaceutical Corporation Information
11.25.2 Reyphon Pharmaceutical Overview
11.25.3 Reyphon Pharmaceutical Dexamethasone for COVID-19 Sales, Price, Revenue and Gross Margin (2017-2022)
11.25.4 Reyphon Pharmaceutical Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
11.25.5 Reyphon Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Dexamethasone for COVID-19 Industry Chain Analysis
12.2 Dexamethasone for COVID-19 Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Dexamethasone for COVID-19 Production Mode & Process
12.4 Dexamethasone for COVID-19 Sales and Marketing
12.4.1 Dexamethasone for COVID-19 Sales Channels
12.4.2 Dexamethasone for COVID-19 Distributors
12.5 Dexamethasone for COVID-19 Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Dexamethasone for COVID-19 Industry Trends
13.2 Dexamethasone for COVID-19 Market Drivers
13.3 Dexamethasone for COVID-19 Market Challenges
13.4 Dexamethasone for COVID-19 Market Restraints
14 Key Findings in The Global Dexamethasone for COVID-19 Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Dexamethasone for COVID-19 Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of 97% Purity
Table 3. Major Manufacturers of 99% Purity
Table 4. Major Manufacturers of Others
Table 5. Global Dexamethasone for COVID-19 Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Dexamethasone for COVID-19 Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Dexamethasone for COVID-19 Sales by Region (2017-2022) & (K Units)
Table 8. Global Dexamethasone for COVID-19 Sales Market Share by Region (2017-2022)
Table 9. Global Dexamethasone for COVID-19 Sales by Region (2023-2028) & (K Units)
Table 10. Global Dexamethasone for COVID-19 Sales Market Share by Region (2023-2028)
Table 11. Global Dexamethasone for COVID-19 Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Dexamethasone for COVID-19 Revenue Market Share by Region (2017-2022)
Table 13. Global Dexamethasone for COVID-19 Revenue by Region (2023-2028) & (US$ Million)
Table 14. Global Dexamethasone for COVID-19 Revenue Market Share by Region (2023-2028)
Table 15. Global Dexamethasone for COVID-19 Sales by Manufacturers (2017-2022) & (K Units)
Table 16. Global Dexamethasone for COVID-19 Sales Share by Manufacturers (2017-2022)
Table 17. Global Dexamethasone for COVID-19 Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 18. Global Dexamethasone for COVID-19 Revenue Share by Manufacturers (2017-2022)
Table 19. Dexamethasone for COVID-19 Price by Manufacturers (2017-2022) &(K USD/K Units)
Table 20. Global Dexamethasone for COVID-19 Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Dexamethasone for COVID-19 by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dexamethasone for COVID-19 as of 2021)
Table 22. Dexamethasone for COVID-19 Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Dexamethasone for COVID-19 Product Offered
Table 24. Date of Manufacturers Enter into Dexamethasone for COVID-19 Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Dexamethasone for COVID-19 Sales by Type (2017-2022) & (K Units)
Table 27. Global Dexamethasone for COVID-19 Sales by Type (2023-2028) & (K Units)
Table 28. Global Dexamethasone for COVID-19 Sales Share by Type (2017-2022)
Table 29. Global Dexamethasone for COVID-19 Sales Share by Type (2023-2028)
Table 30. Global Dexamethasone for COVID-19 Revenue by Type (2017-2022) & (US$ Million)
Table 31. Global Dexamethasone for COVID-19 Revenue by Type (2023-2028) & (US$ Million)
Table 32. Global Dexamethasone for COVID-19 Revenue Share by Type (2017-2022)
Table 33. Global Dexamethasone for COVID-19 Revenue Share by Type (2023-2028)
Table 34. Dexamethasone for COVID-19 Price by Type (2017-2022) & (K USD/K Units)
Table 35. Global Dexamethasone for COVID-19 Price Forecast by Type (2023-2028) & (K USD/K Units)
Table 36. Global Dexamethasone for COVID-19 Sales by Application (2017-2022) & (K Units)
Table 37. Global Dexamethasone for COVID-19 Sales by Application (2023-2028) & (K Units)
Table 38. Global Dexamethasone for COVID-19 Sales Share by Application (2017-2022)
Table 39. Global Dexamethasone for COVID-19 Sales Share by Application (2023-2028)
Table 40. Global Dexamethasone for COVID-19 Revenue by Application (2017-2022) & (US$ Million)
Table 41. Global Dexamethasone for COVID-19 Revenue by Application (2023-2028) & (US$ Million)
Table 42. Global Dexamethasone for COVID-19 Revenue Share by Application (2017-2022)
Table 43. Global Dexamethasone for COVID-19 Revenue Share by Application (2023-2028)
Table 44. Dexamethasone for COVID-19 Price by Application (2017-2022) & (K USD/K Units)
Table 45. Global Dexamethasone for COVID-19 Price Forecast by Application (2023-2028) & (K USD/K Units)
Table 46. North America Dexamethasone for COVID-19 Sales by Type (2017-2022) & (K Units)
Table 47. North America Dexamethasone for COVID-19 Sales by Type (2023-2028) & (K Units)
Table 48. North America Dexamethasone for COVID-19 Revenue by Type (2017-2022) & (US$ Million)
Table 49. North America Dexamethasone for COVID-19 Revenue by Type (2023-2028) & (US$ Million)
Table 50. North America Dexamethasone for COVID-19 Sales by Application (2017-2022) & (K Units)
Table 51. North America Dexamethasone for COVID-19 Sales by Application (2023-2028) & (K Units)
Table 52. North America Dexamethasone for COVID-19 Revenue by Application (2017-2022) & (US$ Million)
Table 53. North America Dexamethasone for COVID-19 Revenue by Application (2023-2028) & (US$ Million)
Table 54. North America Dexamethasone for COVID-19 Sales by Country (2017-2022) & (K Units)
Table 55. North America Dexamethasone for COVID-19 Sales by Country (2023-2028) & (K Units)
Table 56. North America Dexamethasone for COVID-19 Revenue by Country (2017-2022) & (US$ Million)
Table 57. North America Dexamethasone for COVID-19 Revenue by Country (2023-2028) & (US$ Million)
Table 58. Europe Dexamethasone for COVID-19 Sales by Type (2017-2022) & (K Units)
Table 59. Europe Dexamethasone for COVID-19 Sales by Type (2023-2028) & (K Units)
Table 60. Europe Dexamethasone for COVID-19 Revenue by Type (2017-2022) & (US$ Million)
Table 61. Europe Dexamethasone for COVID-19 Revenue by Type (2023-2028) & (US$ Million)
Table 62. Europe Dexamethasone for COVID-19 Sales by Application (2017-2022) & (K Units)
Table 63. Europe Dexamethasone for COVID-19 Sales by Application (2023-2028) & (K Units)
Table 64. Europe Dexamethasone for COVID-19 Revenue by Application (2017-2022) & (US$ Million)
Table 65. Europe Dexamethasone for COVID-19 Revenue by Application (2023-2028) & (US$ Million)
Table 66. Europe Dexamethasone for COVID-19 Sales by Country (2017-2022) & (K Units)
Table 67. Europe Dexamethasone for COVID-19 Sales by Country (2023-2028) & (K Units)
Table 68. Europe Dexamethasone for COVID-19 Revenue by Country (2017-2022) & (US$ Million)
Table 69. Europe Dexamethasone for COVID-19 Revenue by Country (2023-2028) & (US$ Million)
Table 70. Asia Pacific Dexamethasone for COVID-19 Sales by Type (2017-2022) & (K Units)
Table 71. Asia Pacific Dexamethasone for COVID-19 Sales by Type (2023-2028) & (K Units)
Table 72. Asia Pacific Dexamethasone for COVID-19 Revenue by Type (2017-2022) & (US$ Million)
Table 73. Asia Pacific Dexamethasone for COVID-19 Revenue by Type (2023-2028) & (US$ Million)
Table 74. Asia Pacific Dexamethasone for COVID-19 Sales by Application (2017-2022) & (K Units)
Table 75. Asia Pacific Dexamethasone for COVID-19 Sales by Application (2023-2028) & (K Units)
Table 76. Asia Pacific Dexamethasone for COVID-19 Revenue by Application (2017-2022) & (US$ Million)
Table 77. Asia Pacific Dexamethasone for COVID-19 Revenue by Application (2023-2028) & (US$ Million)
Table 78. Asia Pacific Dexamethasone for COVID-19 Sales by Region (2017-2022) & (K Units)
Table 79. Asia Pacific Dexamethasone for COVID-19 Sales by Region (2023-2028) & (K Units)
Table 80. Asia Pacific Dexamethasone for COVID-19 Revenue by Region (2017-2022) & (US$ Million)
Table 81. Asia Pacific Dexamethasone for COVID-19 Revenue by Region (2023-2028) & (US$ Million)
Table 82. Latin America Dexamethasone for COVID-19 Sales by Type (2017-2022) & (K Units)
Table 83. Latin America Dexamethasone for COVID-19 Sales by Type (2023-2028) & (K Units)
Table 84. Latin America Dexamethasone for COVID-19 Revenue by Type (2017-2022) & (US$ Million)
Table 85. Latin America Dexamethasone for COVID-19 Revenue by Type (2023-2028) & (US$ Million)
Table 86. Latin America Dexamethasone for COVID-19 Sales by Application (2017-2022) & (K Units)
Table 87. Latin America Dexamethasone for COVID-19 Sales by Application (2023-2028) & (K Units)
Table 88. Latin America Dexamethasone for COVID-19 Revenue by Application (2017-2022) & (US$ Million)
Table 89. Latin America Dexamethasone for COVID-19 Revenue by Application (2023-2028) & (US$ Million)
Table 90. Latin America Dexamethasone for COVID-19 Sales by Country (2017-2022) & (K Units)
Table 91. Latin America Dexamethasone for COVID-19 Sales by Country (2023-2028) & (K Units)
Table 92. Latin America Dexamethasone for COVID-19 Revenue by Country (2017-2022) & (US$ Million)
Table 93. Latin America Dexamethasone for COVID-19 Revenue by Country (2023-2028) & (US$ Million)
Table 94. Middle East and Africa Dexamethasone for COVID-19 Sales by Type (2017-2022) & (K Units)
Table 95. Middle East and Africa Dexamethasone for COVID-19 Sales by Type (2023-2028) & (K Units)
Table 96. Middle East and Africa Dexamethasone for COVID-19 Revenue by Type (2017-2022) & (US$ Million)
Table 97. Middle East and Africa Dexamethasone for COVID-19 Revenue by Type (2023-2028) & (US$ Million)
Table 98. Middle East and Africa Dexamethasone for COVID-19 Sales by Application (2017-2022) & (K Units)
Table 99. Middle East and Africa Dexamethasone for COVID-19 Sales by Application (2023-2028) & (K Units)
Table 100. Middle East and Africa Dexamethasone for COVID-19 Revenue by Application (2017-2022) & (US$ Million)
Table 101. Middle East and Africa Dexamethasone for COVID-19 Revenue by Application (2023-2028) & (US$ Million)
Table 102. Middle East and Africa Dexamethasone for COVID-19 Sales by Country (2017-2022) & (K Units)
Table 103. Middle East and Africa Dexamethasone for COVID-19 Sales by Country (2023-2028) & (K Units)
Table 104. Middle East and Africa Dexamethasone for COVID-19 Revenue by Country (2017-2022) & (US$ Million)
Table 105. Middle East and Africa Dexamethasone for COVID-19 Revenue by Country (2023-2028) & (US$ Million)
Table 106. Pfizer Corporation Information
Table 107. Pfizer Description and Major Businesses
Table 108. Pfizer Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 109. Pfizer Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 110. Pfizer Recent Developments
Table 111. Novartis Corporation Information
Table 112. Novartis Description and Major Businesses
Table 113. Novartis Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 114. Novartis Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. Novartis Recent Developments
Table 116. Merck & Co. Corporation Information
Table 117. Merck & Co. Description and Major Businesses
Table 118. Merck & Co. Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 119. Merck & Co. Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Merck & Co. Recent Developments
Table 121. Sanofi Pharmaceuticals Corporation Information
Table 122. Sanofi Pharmaceuticals Description and Major Businesses
Table 123. Sanofi Pharmaceuticals Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 124. Sanofi Pharmaceuticals Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. Sanofi Pharmaceuticals Recent Developments
Table 126. Baxter International Corporation Information
Table 127. Baxter International Description and Major Businesses
Table 128. Baxter International Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 129. Baxter International Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. Baxter International Recent Developments
Table 131. Zydus Cadila Corporation Information
Table 132. Zydus Cadila Description and Major Businesses
Table 133. Zydus Cadila Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 134. Zydus Cadila Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. Zydus Cadila Recent Developments
Table 136. Endo International Corporation Information
Table 137. Endo International Description and Major Businesses
Table 138. Endo International Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 139. Endo International Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. Endo International Recent Developments
Table 141. Aspen Pharmacare Holdings Corporation Information
Table 142. Aspen Pharmacare Holdings Description and Major Businesses
Table 143. Aspen Pharmacare Holdings Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 144. Aspen Pharmacare Holdings Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. Aspen Pharmacare Holdings Recent Developments
Table 146. Hikma Pharmaceuticals Corporation Information
Table 147. Hikma Pharmaceuticals Description and Major Businesses
Table 148. Hikma Pharmaceuticals Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 149. Hikma Pharmaceuticals Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. Hikma Pharmaceuticals Recent Developments
Table 151. Cipla Limited Corporation Information
Table 152. Cipla Limited Description and Major Businesses
Table 153. Cipla Limited Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 154. Cipla Limited Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 155. Cipla Limited Recent Developments
Table 156. Wockhardt Limited Corporation Information
Table 157. Wockhardt Limited Description and Major Businesses
Table 158. Wockhardt Limited Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 159. Wockhardt Limited Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 160. Wockhardt Limited Recent Developments
Table 161. Xspire Pharmaceuticals Corporation Information
Table 162. Xspire Pharmaceuticals Description and Major Businesses
Table 163. Xspire Pharmaceuticals Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 164. Xspire Pharmaceuticals Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 165. Xspire Pharmaceuticals Recent Developments
Table 166. Fera Pharmaceuticals Corporation Information
Table 167. Fera Pharmaceuticals Description and Major Businesses
Table 168. Fera Pharmaceuticals Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 169. Fera Pharmaceuticals Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 170. Fera Pharmaceuticals Recent Developments
Table 171. Aché Laboratórios Corporation Information
Table 172. Aché Laboratórios Description and Major Businesses
Table 173. Aché Laboratórios Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 174. Aché Laboratórios Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 175. Aché Laboratórios Recent Developments
Table 176. WraSer Pharmaceuticals Corporation Information
Table 177. WraSer Pharmaceuticals Description and Major Businesses
Table 178. WraSer Pharmaceuticals Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 179. WraSer Pharmaceuticals Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 180. WraSer Pharmaceuticals Recent Developments
Table 181. Mylan Corporation Information
Table 182. Mylan Description and Major Businesses
Table 183. Mylan Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 184. Mylan Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 185. Mylan Recent Developments
Table 186. Bound Tree Medical Corporation Information
Table 187. Bound Tree Medical Description and Major Businesses
Table 188. Bound Tree Medical Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 189. Bound Tree Medical Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 190. Bound Tree Medical Recent Developments
Table 191. Santa Cruz Biotechnology Corporation Information
Table 192. Santa Cruz Biotechnology Description and Major Businesses
Table 193. Santa Cruz Biotechnology Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 194. Santa Cruz Biotechnology Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 195. Santa Cruz Biotechnology Recent Developments
Table 196. KingYork Corporation Information
Table 197. KingYork Description and Major Businesses
Table 198. KingYork Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 199. KingYork Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 200. KingYork Recent Developments
Table 201. Lingrui Pharmaceutical Corporation Information
Table 202. Lingrui Pharmaceutical Description and Major Businesses
Table 203. Lingrui Pharmaceutical Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 204. Lingrui Pharmaceutical Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 205. Lingrui Pharmaceutical Recent Developments
Table 206. North China Pharmaceutical Corporation Information
Table 207. North China Pharmaceutical Description and Major Businesses
Table 208. North China Pharmaceutical Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 209. North China Pharmaceutical Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 210. North China Pharmaceutical Recent Developments
Table 211. Shanghai Shyndec Pharmaceutical Corporation Information
Table 212. Shanghai Shyndec Pharmaceutical Description and Major Businesses
Table 213. Shanghai Shyndec Pharmaceutical Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 214. Shanghai Shyndec Pharmaceutical Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 215. Shanghai Shyndec Pharmaceutical Recent Developments
Table 216. Pharscin Pharmaceutical Corporation Information
Table 217. Pharscin Pharmaceutical Description and Major Businesses
Table 218. Pharscin Pharmaceutical Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 219. Pharscin Pharmaceutical Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 220. Pharscin Pharmaceutical Recent Developments
Table 221. China Resources Sanjiu Pharmaceutical Corporation Information
Table 222. China Resources Sanjiu Pharmaceutical Description and Major Businesses
Table 223. China Resources Sanjiu Pharmaceutical Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 224. China Resources Sanjiu Pharmaceutical Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 225. China Resources Sanjiu Pharmaceutical Recent Developments
Table 226. Reyphon Pharmaceutical Corporation Information
Table 227. Reyphon Pharmaceutical Description and Major Businesses
Table 228. Reyphon Pharmaceutical Dexamethasone for COVID-19 Sales (K Units), Revenue (US$ Million), Price (K USD/K Units) and Gross Margin (2017-2022)
Table 229. Reyphon Pharmaceutical Dexamethasone for COVID-19 Product Model Numbers, Pictures, Descriptions and Specifications
Table 230. Reyphon Pharmaceutical Recent Developments
Table 231. Key Raw Materials Lists
Table 232. Raw Materials Key Suppliers Lists
Table 233. Dexamethasone for COVID-19 Distributors List
Table 234. Dexamethasone for COVID-19 Customers List
Table 235. Dexamethasone for COVID-19 Market Trends
Table 236. Dexamethasone for COVID-19 Market Drivers
Table 237. Dexamethasone for COVID-19 Market Challenges
Table 238. Dexamethasone for COVID-19 Market Restraints
Table 239. Research Programs/Design for This Report
Table 240. Key Data Information from Secondary Sources
Table 241. Key Data Information from Primary Sources
List of Figures
Figure 1. Dexamethasone for COVID-19 Product Picture
Figure 3. Global Dexamethasone for COVID-19 Market Share by Type in 2021 & 2028
Figure 3. 97% Purity Product Picture
Figure 4. 99% Purity Product Picture
Figure 5. Others Product Picture
Figure 6. Global Dexamethasone for COVID-19 Market Share by Application in 2021 & 2028
Figure 7. Hospitals
Figure 8. Clinics
Figure 9. Others
Figure 10. Dexamethasone for COVID-19 Report Years Considered
Figure 11. Global Dexamethasone for COVID-19 Sales 2017-2028 (K Units)
Figure 12. Global Dexamethasone for COVID-19 Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Dexamethasone for COVID-19 Revenue 2017-2028 (US$ Million)
Figure 14. Global Dexamethasone for COVID-19 Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Dexamethasone for COVID-19 Sales Market Share by Region (2017-2022)
Figure 16. Global Dexamethasone for COVID-19 Sales Market Share by Region (2023-2028)
Figure 17. North America Dexamethasone for COVID-19 Sales YoY (2017-2028) & (K Units)
Figure 18. North America Dexamethasone for COVID-19 Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Dexamethasone for COVID-19 Sales YoY (2017-2028) & (K Units)
Figure 20. Europe Dexamethasone for COVID-19 Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Dexamethasone for COVID-19 Sales YoY (2017-2028) & (K Units)
Figure 22. Asia-Pacific Dexamethasone for COVID-19 Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Dexamethasone for COVID-19 Sales YoY (2017-2028) & (K Units)
Figure 24. Latin America Dexamethasone for COVID-19 Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Dexamethasone for COVID-19 Sales YoY (2017-2028) & (K Units)
Figure 26. Middle East & Africa Dexamethasone for COVID-19 Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Dexamethasone for COVID-19 Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Dexamethasone for COVID-19 in the World: Market Share by Dexamethasone for COVID-19 Revenue in 2021
Figure 29. Global Dexamethasone for COVID-19 Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Dexamethasone for COVID-19 Sales Market Share by Type (2017-2028)
Figure 31. Global Dexamethasone for COVID-19 Revenue Market Share by Type (2017-2028)
Figure 32. Global Dexamethasone for COVID-19 Sales Market Share by Application (2017-2028)
Figure 33. Global Dexamethasone for COVID-19 Revenue Market Share by Application (2017-2028)
Figure 34. North America Dexamethasone for COVID-19 Sales Market Share by Type (2017-2028)
Figure 35. North America Dexamethasone for COVID-19 Revenue Market Share by Type (2017-2028)
Figure 36. North America Dexamethasone for COVID-19 Sales Market Share by Application (2017-2028)
Figure 37. North America Dexamethasone for COVID-19 Revenue Market Share by Application (2017-2028)
Figure 38. North America Dexamethasone for COVID-19 Sales Share by Country (2017-2028)
Figure 39. North America Dexamethasone for COVID-19 Revenue Share by Country (2017-2028)
Figure 40. United States Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Dexamethasone for COVID-19 Sales Market Share by Type (2017-2028)
Figure 43. Europe Dexamethasone for COVID-19 Revenue Market Share by Type (2017-2028)
Figure 44. Europe Dexamethasone for COVID-19 Sales Market Share by Application (2017-2028)
Figure 45. Europe Dexamethasone for COVID-19 Revenue Market Share by Application (2017-2028)
Figure 46. Europe Dexamethasone for COVID-19 Sales Share by Country (2017-2028)
Figure 47. Europe Dexamethasone for COVID-19 Revenue Share by Country (2017-2028)
Figure 48. Germany Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 49. France Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Dexamethasone for COVID-19 Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific Dexamethasone for COVID-19 Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific Dexamethasone for COVID-19 Sales Market Share by Application (2017-2028)
Figure 56. Asia Pacific Dexamethasone for COVID-19 Revenue Market Share by Application (2017-2028)
Figure 57. Asia Pacific Dexamethasone for COVID-19 Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Dexamethasone for COVID-19 Revenue Share by Region (2017-2028)
Figure 59. China Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 62. India Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 64. Taiwan Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Dexamethasone for COVID-19 Sales Market Share by Type (2017-2028)
Figure 69. Latin America Dexamethasone for COVID-19 Revenue Market Share by Type (2017-2028)
Figure 70. Latin America Dexamethasone for COVID-19 Sales Market Share by Application (2017-2028)
Figure 71. Latin America Dexamethasone for COVID-19 Revenue Market Share by Application (2017-2028)
Figure 72. Latin America Dexamethasone for COVID-19 Sales Share by Country (2017-2028)
Figure 73. Latin America Dexamethasone for COVID-19 Revenue Share by Country (2017-2028)
Figure 74. Mexico Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 77. Colombia Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 78. Middle East and Africa Dexamethasone for COVID-19 Sales Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Dexamethasone for COVID-19 Revenue Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Dexamethasone for COVID-19 Sales Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Dexamethasone for COVID-19 Revenue Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Dexamethasone for COVID-19 Sales Share by Country (2017-2028)
Figure 83. Middle East and Africa Dexamethasone for COVID-19 Revenue Share by Country (2017-2028)
Figure 84. Turkey Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 85. Saudi Arabia Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 86. UAE Dexamethasone for COVID-19 Revenue (2017-2028) & (US$ Million)
Figure 87. Dexamethasone for COVID-19 Value Chain
Figure 88. Dexamethasone for COVID-19 Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed


【掲載企業】

Pfizer、Novartis、Merck & Co.、Sanofi Pharmaceuticals、Baxter International、Zydus Cadila、Endo International、Aspen Pharmacare Holdings、Hikma Pharmaceuticals、Cipla Limited、Wockhardt Limited、Xspire Pharmaceuticals、Fera Pharmaceuticals、Aché Laboratórios、WraSer Pharmaceuticals、Mylan、Bound Tree Medical、Santa Cruz Biotechnology、KingYork、Lingrui Pharmaceutical、North China Pharmaceutical、Shanghai Shyndec Pharmaceutical、Pharscin Pharmaceutical、China Resources Sanjiu Pharmaceutical、Reyphon Pharmaceutical

★調査レポート[新型コロナウイルス感染症用デキサメタゾンの世界市場インサイト・予測（～2028年）] (コード：QY22MA00001)販売に関する免責事項を必ずご確認ください。
★調査レポート[新型コロナウイルス感染症用デキサメタゾンの世界市場インサイト・予測（～2028年）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • デキサメタゾンリン酸エステルナトリウム製剤の世界市場インサイト・予測（～2028年）
    QY22MA00001 / QYResearch / 2022年3月 / 新型コロナウイルス感染症のパンデミックにより、世界のデキサメタゾンリン酸エステルナトリウム製剤の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にデキサメタゾンリン酸エステルナトリウム製剤の世界市場のxxx％を占める「経口」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国のデキサメタゾンリン酸エステルナトリウム製剤の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのデキサメタゾンリン酸エステルナトリウム製剤市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのデキサメタゾンリン酸エステルナトリウム製剤市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 デキサメタゾンリン酸エステルナトリウム製剤のグローバル主要メーカーには、Pfizer、Novartis、Merck、BioVision、Sanofi Pharmaceuticals、AuroMedics、Baxter International、Fresenius Kabi、Zydus Cadila、Somerset Therapeutics、American Regent、Endo International、Aspen...Dexamethasone Sodium Phosphate Preparation is a synthetic corticosteroid used to treat rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, eye pain following eye surgery, superior vena cava syndrome (a complication of some forms of cancer), and along with antibiotics in tuberculosis. In adrenocortical insufficiency, it may be used in combination with a mineralocorticoid medication such as fludrocortisone. In preterm labor, it may be used to improve outcomes in the baby. It may be given by mouth, as an injection into a muscle, as an injection into a vein, as a topical...
  • 新型コロナウイルス感染症検出キット包装の世界市場インサイト・予測（～2028年）
    QY22MA00001 / QYResearch / 2022年3月 / 新型コロナウイルス感染症のパンデミックにより、世界の新型コロナウイルス感染症検出キット包装の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に新型コロナウイルス感染症検出キット包装の世界市場のxxx％を占める「フォイルバッグ」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「核酸検出キット」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の新型コロナウイルス感染症検出キット包装の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの新型コロナウイルス感染症検出キット包装市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの新型コロナウイルス感染症検出キット包装市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 新型コロナウイルス感染症検出キット包装のグローバル主要メーカーには、Haishun New Pharmaceutical Packaging、CanSinoBIO、Global Printing、Colibri Technologies、JOYSBIO、New Vision Pharmaceuticals、などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。...Market Analysis and Insights: Global COVID-19 Detection Kit Packaging Market Due to the COVID-19 pandemic, the global COVID-19 Detection Kit Packaging market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Foil Bag accounting for % of the COVID-19 Detection Kit Packaging global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Nucleic Acid Detection Kit...
  • 新型コロナウイルス感染症検査キットの世界市場インサイト・予測（～2028年）
    QY22MA00001 / QYResearch / 2022年3月 / 新型コロナウイルス感染症のパンデミックにより、世界の新型コロナウイルス感染症検査キットの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に新型コロナウイルス感染症検査キットの世界市場のxxx％を占める「核酸検査」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の新型コロナウイルス感染症検査キットの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの新型コロナウイルス感染症検査キット市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの新型コロナウイルス感染症検査キット市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 新型コロナウイルス感染症検査キットのグローバル主要メーカーには、Cellex、Abbott、Roche、BioMedomics、BD、Safecare Bio-Tech、Mayo Clinic Laboratories、Chembio Diagnostics、Mount Sinai Laboratory、Ortho Clinical...COVID-19 testing involves analysing samples that indicate the present or past presence of SARS-CoV-2. The two main branches detect either the presence of the virus or antibodies produced in response to infection. Tests for viral presence are used to diagnose illness and to allow public health authorities to identify and contain outbreaks as quickly as possible. Antibody tests instead support attempts to estimate the prevalence of disease within a population. Another, speculative use is to identify individuals who the antibodies have rendered immune to the disease, although research has yet to confirm that a positive test confers such immunity. Individual...
  • 新型コロナウイルス感染症抗体・血清検査キットの世界市場インサイト・予測（～2028年）
    QY22MA00001 / QYResearch / 2022年3月 / 新型コロナウイルス感染症のパンデミックにより、世界の新型コロナウイルス感染症抗体・血清検査キットの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に新型コロナウイルス感染症抗体・血清検査キットの世界市場のxxx％を占める「迅速診断検査（RDT）」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の新型コロナウイルス感染症抗体・血清検査キットの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの新型コロナウイルス感染症抗体・血清検査キット市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの新型コロナウイルス感染症抗体・血清検査キット市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 新型コロナウイルス感染症抗体・血清検査キットのグローバル主要メーカーには、Abbott、Guangzhou Wondfo Biotech、BioMedomics、Kantaro、Roche、Cellex、Innovita Biological Technology、Zhejiang Orient Gene Biotech、Ortho...Serology testing for SARS-CoV-2 is at increased demand in order to better quantify the number of cases of COVID-19, including those that may be asymptomatic or have recovered. Serology tests are blood-based tests that can be used to identify whether people have been exposed to a particular pathogen by looking at their immune response. In contrast, the RT-PCR tests currently being used globally to diagnose cases of COVID-19 can only indicate the presence of viral material during infection and will not indicate if a person was infected and subsequently recovered. These tests can give greater detail into the prevalence of...
  • 新型コロナウイルス感染症検出試薬の世界市場インサイト・予測（～2028年）
    QY22MA00001 / QYResearch / 2022年3月 / 新型コロナウイルス感染症のパンデミックにより、世界の新型コロナウイルス感染症検出試薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に新型コロナウイルス感染症検出試薬の世界市場のxxx％を占める「核酸検出用試薬」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の新型コロナウイルス感染症検出試薬の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの新型コロナウイルス感染症検出試薬市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの新型コロナウイルス感染症検出試薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 新型コロナウイルス感染症検出試薬のグローバル主要メーカーには、Ortho Clinical Diagnostics、Abbott、Camtech Diagnostics、SD Biosensor、Eiken Chemical、BioVendor Group、Andon Health、BGI、JOYSBIO、Synthgene...Market Analysis and Insights: Global COVID-19 Detection Reagent Market Due to the COVID-19 pandemic, the global COVID-19 Detection Reagent market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Nucleic Acid Detection Reagent accounting for % of the COVID-19 Detection Reagent global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to...
  • 新型コロナウイルス感染症迅速抗原の世界市場インサイト・予測（～2028年）
    QY22MA00001 / QYResearch / 2022年3月 / 新型コロナウイルス感染症のパンデミックにより、世界の新型コロナウイルス感染症迅速抗原の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に新型コロナウイルス感染症迅速抗原の世界市場のxxx％を占める「鼻腔ぬぐい液」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の新型コロナウイルス感染症迅速抗原の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの新型コロナウイルス感染症迅速抗原市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの新型コロナウイルス感染症迅速抗原市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 新型コロナウイルス感染症迅速抗原のグローバル主要メーカーには、Abbott、Access Bio、BD、Quidel、Fujirebio、Ellume、OraSure Technologies、Clip Health、Celltrion Healthcare、Salofa Oy、iHealth Labs、Novegent、Hangzhou Alltest...Market Analysis and Insights: Global Covid-19 Rapid Antigen Market Due to the COVID-19 pandemic, the global Covid-19 Rapid Antigen market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Nasal Swab accounting for % of the Covid-19 Rapid Antigen global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an...
  • 新型コロナウイルス感染症抗体・血清検査の世界市場インサイト・予測（～2028年）
    QY22MA00001 / QYResearch / 2022年3月 / 新型コロナウイルス感染症のパンデミックにより、世界の新型コロナウイルス感染症抗体・血清検査の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に新型コロナウイルス感染症抗体・血清検査の世界市場のxxx％を占める「ハイスループットCMIA」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の新型コロナウイルス感染症抗体・血清検査の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの新型コロナウイルス感染症抗体・血清検査市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの新型コロナウイルス感染症抗体・血清検査市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 新型コロナウイルス感染症抗体・血清検査のグローバル主要メーカーには、Abbott Laboratories、Access Bio、Cellex、Babson Diagnostics、Beckman Coulter、Roche、Bio-Rad Laboratories、bioMérieux、DiaSorin、Diazyme Laboratories、Emory Medical...Antibody and serology tests show whether someone has recovered from an infectious disease by looking for the antibodies that fight it in their blood. During the current pandemic, many companies are continuing to develop tests to see if individuals are currently infected by COVID-19, as well as antibody/serology or immunity tests, which represent the next stage of tracking the virus’spread. Market Analysis and Insights: Global COVID-19 Antibody and Serology Tests Market Due to the COVID-19 pandemic, the global COVID-19 Antibody and Serology Tests market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted...
  • 新型コロナウイルス感染症メディカル検査キットの世界市場インサイト・予測（～2028年）
    QY22MA00001 / QYResearch / 2022年3月 / 新型コロナウイルス感染症のパンデミックにより、世界の新型コロナウイルス感染症メディカル検査キットの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に新型コロナウイルス感染症メディカル検査キットの世界市場のxxx％を占める「リアルタイム診断検査」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の新型コロナウイルス感染症メディカル検査キットの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの新型コロナウイルス感染症メディカル検査キット市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの新型コロナウイルス感染症メディカル検査キット市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 新型コロナウイルス感染症メディカル検査キットのグローバル主要メーカーには、Thermo Fisher Scientific、Abbott Laboratories、lnnova、Medybird、Conductive Technologies、RayBiotech、Alercell、Epigentek Group、Atila BioSystems、OraSure Technologies、Accurate...COVID-19 medical testing kits are kits for special targeted detection of the new coronavirus COVID-19. Market Analysis and Insights: Global COVID-19 Medical Testing Kits Market Due to the COVID-19 pandemic, the global COVID-19 Medical Testing Kits market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Real-Time Diagnostic Test accounting for % of the COVID-19 Medical Testing Kits global market in 2021, is projected to value US$ million by...
  • 睡眠覚醒障害の世界市場インサイト・予測（～2028年）
    QY22MA00001 / QYResearch / 2022年3月 / 新型コロナウイルス感染症のパンデミックにより、世界の睡眠覚醒障害の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に睡眠覚醒障害の世界市場のxxx％を占める「不眠症」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「治療法」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の睡眠覚醒障害の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの睡眠覚醒障害市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの睡眠覚醒障害市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 睡眠覚醒障害のグローバル主要メーカーには、Jazz Pharmaceuticals、Koninklijke Philips N.V.、Merck KGaA、Neurocrine Biosciences、RespireRx Pharmaceuticals Inc.、Medtronic...The sleep-wake disorder is a sign of an impending condition such as bipolar disorder. Sleep disorders range from insomnia disorder to narcolepsy and breathing-related disorder to restless leg syndrome. Market Analysis and Insights: Global Sleep-Wake Disorder Market The global Sleep-Wake Disorder market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028. Fully considering the economic change by this health crisis, Insomnia accounting for % of the Sleep-Wake Disorder global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period....
  • エルドシュテインの世界市場インサイト・予測（～2028年）
    QY22MA00001 / QYResearch / 2022年3月 / 新型コロナウイルス感染症のパンデミックにより、世界のエルドシュテインの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にエルドシュテインの世界市場のxxx％を占める「錠剤」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「気管支炎」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国のエルドシュテインの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのエルドシュテイン市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのエルドシュテイン市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 エルドシュテインのグローバル主要メーカーには、Edmond Pharma、Alitair Pharmaceuticals、Zhejiang Kangle Pharmaceutical、Wuhan Yuancheng Pharmaceutical、Shanghai Pukang...Market Analysis and Insights: Global Erdosteine Market Due to the COVID-19 pandemic, the global Erdosteine market size is estimated to be worth US$ 84 million in 2022 and is forecast to a readjusted size of US$ 109.2 million by 2028 with a CAGR of 4.4% during the review period. Fully considering the economic change by this health crisis, Tablets accounting for % of the Erdosteine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Bronchitis segment is altered to an % CAGR throughout this forecast period....

    • ◆H&Iグローバルリサーチのお客様（例）◆